MedTrace Logo

Observational Prospective Study to Evaluate AEs, Risk Factors and Drug Utilization of BUSCAPINA COMPOSITUM N in Adults From Metropolitan Lima

NCT02910167 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 360

Last updated 2019-03-27

Study results available
· View outcomes & findings →

Summary

What AE occur in routine clinical practice, what is the incidence of AE and Adverse Drug Reaction, how many patients present with AE symptoms related to a potential liver injury. What are the drug utilization patterns in patients, what are the predisposing factors for the occurrence of adverse events and adverse drug reactions.

Conditions

  • Acute Pain
  • Dysmenorrhea

Interventions

DRUG

Hyoscine n-butylbromide

Hyoscine n-butylbromide 10 mg

DRUG

Paracetamol

Paracetamol 500 mg

DRUG

Hyoscine n-butylbromide

Hyoscine n-butylbromide 10 mg

DRUG

Paracetamol

Paracetamol 500 mg

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-15
Primary Completion
2017-02-20
Completion
2017-02-20

Countries

  • Peru

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02910167 on ClinicalTrials.gov